Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cure VCP Disease is a U.S.-based nonprofit rare-disease organization focused on accelerating treatments and cures for disorders caused by pathogenic variants in the VCP gene, especially VCP-associated multisystem proteinopathy/IBMPFD. Rather than operating as a traditional drug developer, it functions as a patient advocacy and translational research organization that funds and coordinates preclinical tools, natural history studies, biomarker work, registry development, and clinical-trial readiness initiatives. Its research strategy spans small-molecule discovery, DNA/RNA modulation approaches, and gene-editing collaborations intended to enable future therapeutic programs. The organization also supports patients and clinicians through education, community building, and disease-management resources, while convening academic, industry, and patient stakeholders around VCP disease.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cure VCP Disease.